Cite
HARVARD Citation
Perrino, M. et al. (2022). Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy. Cancer. 128 (4), pp. 719-726. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Perrino, M. et al. (2022). Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy. Cancer. 128 (4), pp. 719-726. [Online].